According to FutureWise analysis the market for saxagliptin in 2023 is US$ 0.21 billion, and is expected to reach US$ 0.3 billion by 2031 at a CAGR of 4.40%.
Saxagliptin is an oral hypoglycemic drug (anti-diabetic drug), sold under the trade name Onglyza. AstraZeneca collaborated with Bristol-Myers Squibb in the development of the final compound as well as the marketing of this drug. Saxagliptin can be used to treat type 2 diabetes mellitus. To lower blood sugar, it should be used in combination with healthy eating habits and regular exercise. This helps to avoid severe complications of diabetes such as blindness and kidney damage. There was no comparison of saxagliptin and basal insulin therapy over metformin monotherapy. This alternative therapy is tier 1 according to the ADA-EASD consensus.
The investigation found that metformin plus saxagliptin can be used in combination with insulin therapy for the treatment of Type 2 Diabetes Mellitus (T2DM). However, it did not compare saxagliptin and basal insulin in addition to baseline metformin monotherapy. Onglyza (TM), a powerful and easily bioavailable, reversible inhibitor of dipeptidyl peptidase IV, (DPPIV), was approved by the U.S. Food and Drug Administration in 2009 for the treatment of type 2 diabetes mellitus. In keeping with this mechanism, saxagliptin treatment also led to statistically significant reductions in Post Prandial Glucose. These were related to higher postprandial insulin levels and C-peptide UUC levels than metformin plus placebo. This suggests that saxagliptin increased postprandial glucose responsiveness. The body's response (or glucose tolerance) to glucose is measured using the glucose tolerance test. To screen for type 2, the oral glucose tolerance test can be used.
Saxagliptin can be used in monotherapy or combined with other drugs to treat type II diabetes. It doesn't appear to lower the likelihood of strokes or heart attacks. It can increase the risk of heart failure hospitalization by around 27%. It is similar to other DPP-4 inhibitors in that it has a low HbA1c level, does not cause weight gain, and has a limited ability to lower blood sugar. In a 24-week study of type 2 diabetics, Saxagliptin significantly improved mean HbA1c levels (relative to placebo). Combination therapy with metformin and saxagliptin was more effective than monotherapy or saxagliptin. In a study of 768 patients, the relative effectiveness of increasing the dosage of Sulfonylurea and adding saxagliptin was evaluated. Combination treatments had a significantly higher impact on fasting glucose levels than increasing the tested dose of glibenclamide. Patients with type 2 diabetes, where blood sugar levels are too high due to a lack of insulin production or use, can take saxagliptin along with exercise and diet. Saxagliptin belongs to a group of medications called dipeptidyl peptidase-4 inhibitors (DPP-4). It increases the body's ability to produce insulin after high-blood-sugar meals. Saxagliptin cannot be used to treat type 1 diabetes (a condition in which the body doesn't produce insulin, and therefore can not control blood sugar) or diabetic ketoacidosis, which is a serious condition that can develop if it isn't treated.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Saxagliptin Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Saxagliptin Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.